By Dr Louise Emmett

Journal articles

Lieng H; Kneebone A; Hayden AJ; Christie DRH; Davis BJ; Eade TN; Emmett L; Holt T; Hruby G; Pryor D; Sidhom M; Skala M; Yaxley J; Shakespeare TP, 2019, 'Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group', Radiotherapy and Oncology, 140, pp. 68 - 75, http://dx.doi.org/10.1016/j.radonc.2019.05.016

Hofman MS; Emmett L; Violet J; Y. Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; Davis ID, 2019, 'TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)', BJU International, 124, pp. 5 - 13, http://dx.doi.org/10.1111/bju.14876

Hofman MS; Emmett L, 2019, 'Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength?', European Urology, 76, pp. 479 - 481, http://dx.doi.org/10.1016/j.eururo.2019.07.030

van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L, 2019, 'Gallium-68-prostate-specific membrane antigen (68Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer', BJU International, 124, pp. 62 - 68, http://dx.doi.org/10.1111/bju.14506

Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM, 2019, 'Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial', Lancet Oncology, 20, pp. 961 - 971, http://dx.doi.org/10.1016/S1470-2045(19)30331-6

Fendler WP; Calais J; Eiber M; Flavell RR; Mishoe A; Feng FY; Nguyen HG; Reiter RE; Rettig MB; Okamoto S; Emmett L; Zacho HD; Ilhan H; Wetter A; Rischpler C; Schoder H; Burger IA; Gartmann J; Smith R; Small EJ; Slavik R; Carroll PR; Herrmann K; Czernin J; Hope TA, 2019, 'Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial', JAMA Oncology, 5, pp. 856 - 863, http://dx.doi.org/10.1001/jamaoncol.2019.0096

Yin C; Ho B; Chan L; Emmett L, 2019, 'Asymptomatic Prostate Cancer Brain Metastases on 68Ga-PSMA PET/CT', Clinical Nuclear Medicine, 44, pp. E382 - E384, http://dx.doi.org/10.1097/RLU.0000000000002548

Emmett L; Metser U; Bauman G; Hicks RJ; Weickhardt A; Davis ID; Punwani S; Pond G; Chua S; Ho B; Johnston E; Pouliot F; Scott AM, 2019, 'Prospective, multisite, international comparison of 18F-fluoromethylcholine PET/CT, multiparametric MRI, and 68Ga-HBED-CC PSMA-11 PET/CT in men with high-risk features and biochemical failure after radical prostatectomy: Clinical performance and patient outcomes', Journal of Nuclear Medicine, 60, pp. 794 - 800, http://dx.doi.org/10.2967/jnumed.118.220103

Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM, 2019, 'Results of a Prospective Phase 2 Pilot Trial of 177 Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression', Clinical Genitourinary Cancer, 17, pp. 15 - 22, http://dx.doi.org/10.1016/j.clgc.2018.09.014

Nandurkar R; Van Leeuwen P; Stricker P; Woo H; Kooner R; Yuen C; O'Neill G; Ende D; Cusick T; Ho B; Hickey A; Emmett L, 2019, '68Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery', British Journal of Radiology, 92, http://dx.doi.org/10.1259/bjr.20180667

van Leeuwen PJ; Emmett L; Donswijk ML; Stricker PD; Pos FJ; Wit E; van der Poel HG, 2019, 'Early outcomes after [68Ga]PSMA-PET/CT guided salvage therapy in men with biochemical recurrence after radical prostatectomy', Tijdschrift Voor Urologie, 9, pp. 2 - 8, http://dx.doi.org/10.1007/s13629-018-00215-w

Crumbaker M; Emmett L; Horvath LG; Joshua AM, 2019, 'Exceptional response to 177lutetium prostate-specific membrane antigen in prostate cancer harboring DNA repair defects', JCO Precision Oncology, 3, pp. 1 - 5, http://dx.doi.org/10.1200/PO.18.00237

Emmett L; Yin C; Crumbaker M; Hruby G; Kneebone A; Epstein R; Nguyen Q; Hickey A; Ihsheish N; O'Neill G; Horvath L; Chalasani V; Stricker P; Joshua AM, 2019, 'Rapid modulation of PSMA expression by androgen deprivation: Serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade', Journal of Nuclear Medicine, 60, pp. 950 - 954, http://dx.doi.org/10.2967/jnumed.118.223099

Metser U; Chua S; Ho B; Punwani S; Johnston E; Pouliot F; Tau N; Hawsawy A; Anconina R; Bauman G; Hicks RJ; Weickhardt A; Davis ID; Pond G; Scott AM; Tunariu N; Sidhu H; Emmett L, 2019, 'The contribution of multiparametric pelvic and whole-body MRI to interpretation of 18F-fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in patients with biochemical failure after radical prostatectomy', Journal of Nuclear Medicine, 60, pp. 1253 - 1258, http://dx.doi.org/10.2967/jnumed.118.225185

Liu W; Fakir H; Randhawa G; Kassam Z; Chung HT; Chung P; Ward A; Zukotynski K; Emmett L; Bauman G, 2019, '2 Drive: Defining Radiorecurrent Intraprostatic Target Volumes', Radiotherapy and Oncology, 139, pp. S4 - S4, http://dx.doi.org/10.1016/s0167-8140(19)33259-1

Long GV; Atkinson VG; Lo S; Sandhu SK; Brown M; Gonzalez M; Guminski A; Scolyer RA; Emmett L; Menzies AM; McArthur GA, 2019, 'Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC)', Annals of Oncology, 30, pp. v534 - v534, http://dx.doi.org/10.1093/annonc/mdz255.001

Lieng H; Hayden AJ; Christie DRH; Davis BJ; Eade TN; Emmett L; Holt T; Hruby G; Pryor D; Shakespeare TP; Sidhom M; Skala M; Wiltshire K; Yaxley J; Kneebone A, 2018, 'Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group', Radiotherapy and Oncology, 129, pp. 377 - 386, http://dx.doi.org/10.1016/j.radonc.2018.06.027

Tan AC; Emmett L; Lo S; Liu V; Kapoor R; Carlino MS; Guminski AD; Long GV; Menzies AM, 2018, 'FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma', Annals of Oncology, 29, pp. 2115 - 2120, http://dx.doi.org/10.1093/annonc/mdy330

Hruby G; Eade T; Emmett L; Ho B; Hsiao E; Schembri G; Guo L; Kwong C; Hunter J; Byrne K; Kneebone A, 2018, '68Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer', Asia Pacific Journal of Clinical Oncology, 14, pp. 343 - 346, http://dx.doi.org/10.1111/ajco.12872

Hope TA; Afshar-Oromieh A; Eiber M; Emmett L; Fendler WP; Lawhn-Heath C; Rowe SP, 2018, 'Imaging prostate cancer with prostate-specific membrane antigen PET/CT and PET/MRI: Current and future applications', American Journal of Roentgenology, 211, pp. 286 - 294, http://dx.doi.org/10.2214/AJR.18.19957

Byrne K; Eade T; Kneebone A; Guo L; Hsiao E; Schembri G; Kwong C; Hunter J; Emmett L; Hruby G, 2018, 'Delineating sites of failure following post-prostatectomy radiation treatment using 68Ga-PSMA-PET', Radiotherapy and Oncology, 126, pp. 244 - 248, http://dx.doi.org/10.1016/j.radonc.2017.10.022

Deenick EK; Morey A; Danta M; Emmett L; Fay K; Gracie G; Ma CS; Macintosh R; Smith SABC; Sasson SC; Sewell WA; Cowley M; Tangye SG; Kelleher AD; Phan TG, 2018, 'Reversible Suppression of Lymphoproliferation and Thrombocytopenia with Rapamycin in a Patient with Common Variable Immunodeficiency', Journal of Clinical Immunology, 38, pp. 159 - 162, http://dx.doi.org/10.1007/s10875-018-0477-z

Roach PJ; Francis R; Emmett L; Hsiao E; Kneebone A; Hruby G; Eade T; Nguyen QA; Thompson BD; Cusick T; McCarthy M; Tang C; Ho B; Stricker PD; Scott AM, 2018, 'The impact of 68 Ga-PSMA PET/CT on management intent in prostate cancer: Results of an australian prospective multicenter study', Journal of Nuclear Medicine, 59, pp. 82 - 88, http://dx.doi.org/10.2967/jnumed.117.197160

, 2018, '2018 CUA Abstracts.', Can Urol Assoc J, 12, pp. S51 - S136, https://www.ncbi.nlm.nih.gov/pubmed/29877793

Pouliot F; Bauman G; Chua S; Davis I; Hicks R; Metser U; Punwani S; Scott A; Weickhardt A; Emmett L, 2018, 'PD37-02 A PROSPECTIVE MULTICENTER STUDY COMPARING MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING (MP-MRI), F-18 FLUORO-METHYL-CHOLINE (FCH) AND GA-68 HBED-CC- (PSMA) POSITRON EMISSION TOMOGRAPHY IN PATIENTS BEING CONSIDERED FOR SALVAGE RADIATION THERAPY FOR BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY', Journal of Urology, 199, http://dx.doi.org/10.1016/j.juro.2018.02.1737

Emmett L; Metzer U; Bauman G; Pouliot F; Hicks R; Chua S; Davis I; Punwani S; Weikhardt A; Scott A, 2018, 'Prospective, multinational comparison of magnetic resonance imaging (mp-MRI and WB–MRI) F-18 fluorocholine (FCH) and Ga-68 PSMA in high risk men being considered for salvage radiation treatment for biochemical failure post radical prostatectomy', European Urology Supplements, 17, pp. e583 - e583, http://dx.doi.org/10.1016/s1569-9056(18)31246-6

Emmett L; Nandurkar R; Van Leeuwen P; Woo H; Kooner R; Ende D; O’Neill G; Yuen C; Ho B; Nguyen Q; Hickey A; Stricker P, 2018, 'Staging with Ga-68 HBED-CC-Glu-NH-CO-NH-Lys (Ahx) PSMA-11 PET CT (PSMA) prior to radical prostatectomy has high predictive value in assessing biochemical response to surgery', European Urology Supplements, 17, pp. e1903 - e1903, http://dx.doi.org/10.1016/s1569-9056(18)32310-8

Fennessy N; Lee J; Shin J; Ho B; Ali SA; Paschkewitz R; Emmett L, 2017, 'Frusemide aids diagnostic interpretation of 68Ga-PSMA positron emission tomography/CT in men with prostate cancer', Journal of Medical Imaging and Radiation Oncology, 61, pp. 739 - 744, http://dx.doi.org/10.1111/1754-9485.12625

Emmett L; Van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P, 2017, 'Treatment outcomes from 68Ga-PSMA PET/CT-informed salvage radiation treatment in men with rising PSA after radical prostatectomy: Prognostic value of a negative PSMA PET', Journal of Nuclear Medicine, 58, pp. 1972 - 1976, http://dx.doi.org/10.2967/jnumed.117.196683

Siriwardana A; Thompson J; van Leeuwen PJ; Doig S; Kalsbeek A; Emmett L; Delprado W; Wong D; Samaratunga H; Haynes AM; Coughlin G; Stricker P, 2017, 'Initial multicentre experience of 68gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited', BJU International, 120, pp. 673 - 681, http://dx.doi.org/10.1111/bju.13919

Fendler WP; Calais J; Allen-Auerbach M; Bluemel C; Eberhardt N; Emmett L; Gupta P; Hartenbach M; Hope TA; Okamoto S; Helmut Pfob C; Pöppel TD; Rischpler C; Schwarzenböck S; Stebner V; Unterrainer M; Zacho HD; Maurer T; Gratzke C; Crispin A; Czernin J; Herrmann K; Eiber M, 2017, '68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: An international multicenter prospective study', Journal of Nuclear Medicine, 58, pp. 1617 - 1623, http://dx.doi.org/10.2967/jnumed.117.190827

Fanti S; Minozzi S; Morigi JJ; Giesel F; Ceci F; Uprimny C; Hofman MS; Eiber M; Schwarzenbock S; Castellucci P; Bellisario C; Chauvie S; Bergesio F; Emmett L; Haberkorn U; Virgolini I; Schwaiger M; Hicks RJ; Krause BJ; Chiti A, 2017, 'Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions', European Journal of Nuclear Medicine and Molecular Imaging, 44, pp. 1622 - 1635, http://dx.doi.org/10.1007/s00259-017-3725-1

Calopedos RJS; Chalasani V; Asher R; Emmett L; Woo HH, 2017, 'Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: A systematic review and meta-analysis', Prostate Cancer and Prostatic Diseases, 20, pp. 352 - 360, http://dx.doi.org/10.1038/pcan.2017.23

Stodell M; Thompson JF; Emmett L; Uren RF; Kapoor R; Saw RPM, 2017, 'Melanoma patient imaging in the era of effective systemic therapies', European Journal of Surgical Oncology, 43, pp. 1517 - 1527, http://dx.doi.org/10.1016/j.ejso.2017.05.014

Long GV; Atkinson V; Menzies AM; Lo S; Guminski AD; Brown MP; Gonzalez MM; Diamante K; Sandhu SK; Scolyer RA; Emmett L; McArthur GA, 2017, 'A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).', Journal of Clinical Oncology, 35, pp. 9508 - 9508, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.9508

Emmett L; Willowson K; Violet J; Shin J; Blanksby A; Lee J, 2017, 'Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy', Journal of Medical Radiation Sciences, 64, pp. 52 - 60, http://dx.doi.org/10.1002/jmrs.227

van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD, 2017, 'Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer', BJU International, 119, pp. 209 - 215, http://dx.doi.org/10.1111/bju.13540

Hruby G; Eade T; Kneebone A; Emmett L; Guo L; Ho B; Hsiao E; Schembri G; Hunter J; Kwong C, 2017, 'Delineating biochemical failure with 68Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer', Radiotherapy and Oncology, 122, pp. 99 - 102, http://dx.doi.org/10.1016/j.radonc.2016.11.023

Holtkamp LHJ; Read RL; Emmett L; Thompson JF; Nieweg OE, 2017, 'Futility of imaging to stage melanoma patients with a positive sentinel lymph node', Melanoma Research, 27, pp. 457 - 462, http://dx.doi.org/10.1097/CMR.0000000000000362

Gonzalez M; Menzies AM; Saw R; Thompson JF; Spillane AJ; Howle J; Nieweg O; Shannon K; Ch'Ng S; Stretch JF; Carlino MS; Guminski A; Emmett L; Rizos H; Scolyer RA; Long GV, 2017, 'A Phase II, Randomised, Open Label Study of Neoadjuvant Pembrolizumab with/without Dabrafenib and Trametinib (D+T) in BRAF V600 Mutant Resectable Stage IIIB/C/D Melanoma (NeoTrio Trial)', Annals of Oncology, 28, pp. v445 - v445, http://dx.doi.org/10.1093/annonc/mdx377.041

Menzies AM; Gonzalez M; Guminski A; Nieweg O; Shannon K; Thompson JF; Kefford R; Ch'Ng S; Stretch J; Spillane AJ; Lee J; Lee H; Kapoor R; Emmett L; Rizos H; Saw RP; Scolyer RA; Long GV, 2017, 'Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma', Annals of Oncology, 28, pp. v432 - v432, http://dx.doi.org/10.1093/annonc/mdx377.007

Bhatia KD; Ambati C; Dhaliwal R; Paschkewitz R; Hsu E; Ho B; Young A; Emmett L, 2016, 'SPECT-CT/VQ versus CTPA for diagnosing pulmonary embolus and other lung pathology: Pre-existing lung disease should not be a contraindication', Journal of Medical Imaging and Radiation Oncology, 60, pp. 492 - 497, http://dx.doi.org/10.1111/1754-9485.12471

Kanthan GL; Izard MA; Emmett L; Hsiao E; Schembri GP, 2016, 'Schwannoma showing avid uptake on 68Ga-PSMA-HBED-CC PET/CT', Clinical Nuclear Medicine, 41, pp. 703 - 704, http://dx.doi.org/10.1097/RLU.0000000000001281

Long GV; Atkinson V; Menzies AM; Guminski AD; Sandhu SK; Brown MP; Liaw T; Gonzalez M; Davison J; Paton EJ; Scolyer RA; Emmett L; McArthur GA, 2016, 'A randomized phase 2 study of nivolumab and nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases: The Anti-PD1 Brain Collaboration (ABC Study).', Journal of Clinical Oncology, 34, pp. TPS9591 - TPS9591, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.tps9591

Lee P; Bova R; Schofield L; Bryant W; Dieckmann W; Slattery A; Govendir MA; Emmett L; Greenfield JR, 2016, 'Brown Adipose Tissue Exhibits a Glucose-Responsive Thermogenic Biorhythm in Humans', Cell Metabolism, 23, pp. 602 - 609, http://dx.doi.org/10.1016/j.cmet.2016.02.007

Tang R; Wang JTY; Wang L; Le K; Huang Y; Hickey AJ; Emmett L, 2016, 'Impact of patient preparation on the diagnostic performance of 18F-FDG PET in cardiac sarcoidosis a systematic review and meta-analysis', Clinical Nuclear Medicine, 41, pp. e327 - e339, http://dx.doi.org/10.1097/RLU.0000000000001063

Van Leeuwen PJ; Emmett L; Hruby G; Kneebone A; Stricker P, 2016, '548 68Ga-PSMA has high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment', European Urology Supplements, 15, pp. e548 - e548, http://dx.doi.org/10.1016/s1569-9056(16)60550-x

Van Leeuwen P; Emmett L; Ho B; Delprado W; Stricker P, 2016, '559 Prospective evaluation of 68Ga-PSMA positron emission tomography/computerized tomography for preoperative lymph node staging in prostate cancer', European Urology Supplements, 15, pp. e559 - e559, http://dx.doi.org/10.1016/s1569-9056(16)60561-4

Emmett L, 2015, '68Ga-PSMA has high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.', BJU International

Morigi JJ; Stricker PD; Van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L, 2015, 'Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy', Journal of Nuclear Medicine, 56, pp. 1185 - 1190, http://dx.doi.org/10.2967/jnumed.115.160382

Back to profile page